Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First Three-Parent Baby Born As A Result Of New Fertility Technique

XTALKS VITALS NEWS

Embryo

If the promising results from the animal studies can be reproduced in humans, the blood vessel grafts could reduce the number of surgeries needed to correct congenital heart defects in children.

Tweetables from this article:

Tweet: New technique will allow parents with rare mitochondrial mutations to have healthy children #mitochondrialdisease http://ctt.ec/k3437+New technique will allow parents with rare mitochondrial mutations to have healthy children.

Share this!

September 29, 2016 | by Sarah Hand, M.Sc.

Using a new technique which combines the genetic material from three people, a baby boy with three biological parents has been born. Now five-months-old, the boy carries DNA from his mother, his father and a third egg donor.

The groundbreaking technique will allow parents with rare mitochondrial mutations to have healthy children. While the technique is currently only approved in the UK, embryologists say the birth of this child will spur more approvals around the world.

The mother of the child carries a mutation for a fatal nervous system disorder known as Leigh syndrome in her mitochondrial DNA. As mitochondrial DNA is passed down through the maternal line, any naturally-conceived children could inherit the life-threatening mutation.

Approximately 25 percent of her mitochondria contain the gene for Leigh syndrome, however the disorder does not affect her. After her first two children died as a result of the disorder, the Jordanian couple sought the help of New York City-based fertility specialist, Dr. John Zhang of the New Hope Fertility Center.

In order to prevent the mitochondrial disease, Zhang and his colleagues have been developing various three-parent techniques. Pronuclear transfer – the method that is currently approved in the UK – involves fertilizing the mother’s egg and a donor egg with sperm collected from the father. Each nucleus is removed from the fertilized eggs before they move into early-stage embryos, and the nucleus from the mother’s fertilized egg is used to replace that taken from the donor’s embryo.



In this case, since two embryos are destroyed in the pronuclear transfer process, it was an inappropriate procedure for the Muslim parents. Instead, Zhang removed the nucleus from a donor egg and replaced it with the nucleus from the mother’s egg before fertilization. In a process known as spindle nuclear transfer, the resulting egg was fertilized with the father’s sperm.

Since the technique is not currently approved in the US, Zhang and his team travelled to Mexico to complete the procedure. According to Zhang, his decision to use the three parent technique was the right one. “To save lives is the ethical thing to do,” said Zhang.

The boy is showing no signs of Leigh syndrome and less than one percent of his mitochondria were found to carry the disease-causing mutation. Zhang is hopeful that this will be too few copies of the mutation to cause symptoms, as 18 percent of mitochondria must carry the gene before the disease manifests itself.

While this technique appears to be safe so far, reproductive medicine has had a less-than-perfect track record when it comes to experimental procedures. In the 1990s, a three-person technique – whereby mitochondrial DNA from a donor was injected into a fertilized egg – resulted in babies with genetic disorders. While the technique was eventually banned, some believe that the problems were a result of the babies’ cells containing two sets of genetically-distinct mitochondria.


Keywords: Mitochondrial DNA, Mutation, Fertility


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.